#Live-Stock Pharma Company

[mostlysignssomeportents]

Trump gave Moderna all the patent-waivers it needed to make a vaccine

There’s a lot of competition for the title of “Most On-The-Nose Symbol of Late Stage Capitalism,” but I think there’s a strong case for awarding the crown to “Vaccine Apartheid” — the decision to deny covid vaccines to billions of poor people in the Global South.

Here’s how that went down: countries in the poor world were arm-twisted into signing the WTO agreement on pain of being shut out of global trade (these former colonies had all been forcibly converted to export crop economies that relied on rich-world countries for seed and Big Ag tech, so opting out of trade wasn’t an option).

Part of the WTO is the TRIPS (AKA “Agreement on Trade-Related Aspects of Intellectual Property Rights”) — a treaty that binds WTO members to respect each others’ patent rights. This is an inarguably bad deal for poor countries, which is why the USA didn’t respect foreign patents until they became a net patent exporter.

One way this can go horribly wrong? Pharmaceuticals. The marginal costs of producing most drugs are very low, but Big Pharma wants to charge all the traffic can bear — markups of tens of thousands of percent! They say this is to recoup R&D, but R&D costs are largely borne by public institutions, with pharma giants privatizing the gains from those public expenditures.

Once a drug is invented and tested, it can be made very cheaply, so poor countries could benefit from it, even given their very modest means, and poor countries can’t afford to pay rich world prices. Cheap drug prices for the global south won’t cut into full-price sales for the poorest 3 billion people. They’re not ever gonna pay US prices.

But this still would be bad for pharma’s business model, which is predicated on raking in those five-figure margins from people in the rich world, some of whom are quite poor (thanks, inequality!). If there’s a low-cost source of pharma’s products somewhere else in the world, then desperate people in the rich world will figure out how to import those low-cost drugs, and a giant pharma company’s stock buybacks and dividends will be reduced from hella-billions to mere umpty-billions.

So if you’re a poor country, signing onto the WTO and the TRIPS means that nearly everyone in your country just won’t have access to lifesaving drugs. This is such an obvious bad deal that the WTO negotiators from the global south balked at it, so the WTO threw them a bone: IP Waivers.

https://pluralistic.net/2021/05/25/the-other-shoe-drops/#quid-pro-quo

Here’s how those (are supposed to) work: if there’s a terrible emergency, say, a pandemic, then the WTO can grant “IP Waivers” to poor countries, which say, “Since this is such an humanitarian disaster, we’re going to temporarily lift your obligation to respect rich, offshore corporations’ patents. You can make their drugs, or import them from another poor country that’s doing so.” Sometimes these waivers make it free to use foreign companies’ patents, other times, they set a fixed cost (a “compulsory license”) for practicing a patent.

IP Waivers are as much as part of the global patent system as patent protections are: they’re the quid-pro-quo that justified poor countries’ tying their own hands and agreeing not to make drugs that would improve the quality of life for the people who live there.

But corporatists and Ayn Rand trufans hate IP Waivers. Back when South Africa and other global south countries were in danger of collapsing under the AIDS pandemic, they petitioned the WTO for an IP Waiver for AIDS drugs, which were otherwise priced beyond their means.

They had a real shot at it, too! But then, the Gates Foundation (yes, that Gates Foundation) sent its operatives to Geneva to argue against any such thing, insisting sovereign countries should beg rich foreigners to donate medicine to them, and if the rich foreigners didn’t want to, they should just let their people die and their nation fail:

https://pluralistic.net/2021/04/13/public-interest-pharma/#gates-foundation

Gates and his Foundation epitomize the idea that the only way to organize public health issues is through the whims of unaccountable billionaires, rather than democratically elected governments. When Oxford University announced plans to make its vaccine patent-free, Gates changed their mind, talking them into an exclusive deal with Astrazeneca instead:

https://khn.org/news/rather-than-give-away-its-covid-vaccine-oxford-makes-a-deal-with-drugmaker/

Rather than trusting billions in the global south to decide how to make and distribute vaccines, Gates set up a program called COVAX, whereby rich people and rich countries could donate covid vaccines — enough to treat just a tiny slice of the world’s poorest people.

https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines

Meanwhile, at the WTO, the global south showed up calling for an IP Waiver for covid vaccines. The rich world’s pharma companies having laid out plans to delay vaccination until 2025 for 2.5 billion people in 125 countries, the case for a covid vax waiver was very strong.

Big Pharma went on the offensive. They paid ghoulish “experts” — like Howard Dean, now an unregistered pharma lobbyist — to spread the racist lie that poor brown people are too stupid to make their own vaccines (the largest vaccine factories are in the global south).

https://pluralistic.net/2021/05/21/wait-your-turn/#vaccine-apartheid

They also promoted the dangerous, medically incoherent theory that poor people should “wait their turn.” This isn’t merely an inhumane, vicious ideology, it’s also a recipe for cooking up lot of covid variants, including those that escape vaccine immunity and re-infect people in the rich world. Leaving 2.5 billion people unvaccinated for years and years, incubating variant after variant, is the gift that keeps on giving…to the virus.

The idea that we can deny vaccines to half the world is like the idea that we can create a swimming pool with a "pissing" and "non-pissing" end, and doom all the people who can't afford the pay toilets to swim in the pissing end - without all of us marinating in piss.

It’s…ironic? Tragic? Tragironic? Because, of course, the vaccines were made with public money — direct state intervention in the market, in the form of R&D and production subsidies and purchase guarantees. The people insisting that unfettered markets are the only way to produce vaccines are manifestly wrong.

https://pluralistic.net/2021/05/16/entrepreneurial-state/#patient-zero-money

To its credit, the Biden administration backed the IP Waivers, but they didn’t throw a lot of weight behind it, and the corporate lobby outmaneuvered them, killing waivers by arguing that any kind of IP Waiver would be the end of vaccine production forever:

https://pluralistic.net/2021/05/10/comrade-ustr/#vaccine-diplomacy

But now, a trove of Trump administration documents that Knowledge Ecology International (KEI) forced the US government to release shows that these very same pharma companies enjoyed luxuriant, expansive IP Waivers of their own. Writing in The Intercept, Lee Fang details how Moderna, in particular, demanded and received waivers:

https://theintercept.com/2022/08/23/covid-vaccine-patents-moderna-big-pharma-section-1498/

All in all, the Trump admin granted IP Waivers to 62 US companies making drugs, PPE, and medical equipment. These waivers allowed their recipients to march into their rivals’ patent rights and seize them, without permission, in order to produce the drugs, supplies and equipment needed to fight the virus.

These waivers were granted under 28USC§1498 (aka Section 1498), a rule that allows government contractors to demand a compulsory license to their rivals’ patents, indemnifying them — and often, the government — from patent liability. Beneficiaries of the S1498 waivers include Moderna, but also Corning, Eli Lilly, Merck, Qiagen, Sanofi and Siemens.

S1498 dates back to 1910 and came into widespread use in WWI, when the US government expropriated the Wright Brothers’ airplane patents to create an air force. S1498 got another lift in WWII, under similar circumstances.

It has been quiescent since, and, indeed, the Trump administration kept its use of waivers a secret. KEI was tipped off to their use thanks to a lawsuit filed by two of Moderna’s competitors, who complained that Moderna “simply used the patented technology without paying for it or even asking for a license.”

KEI cofounder James Love told Fang that he supports the use of waivers for covid vaccines: “I’m glad they did it.” But he pointed out that even as Moderna was relying on these waivers, they were also denouncing the idea of waivers for poor countries as an existential risk to all pharma research.

Meanwhile, Moderna’s vaccine was “really one of the most profitable biopharmaceutical products of all time.” The CEO who oversaw its production has liquidated $400m in stock. The company received $2.48b in public subsidy to make the vaccine.

Anyway, enjoy your variants. Mask up, everyone!

[Image ID: The Earth, floating in space, with its southern hemisphere in flames; it is being irradiated by a beam-weapon fired by a Death Star-style coronavirus molecule, bearing the Moderna logo.]

#pluralistic

[reddancer1]

Bernie takes on Big Pharma

There is a lot of discussion about how "divided" our nation is and, on many issues, that is absolutely true.

But if you ask most Americans — Democrats, Republicans, independents, progressives, conservatives — they will agree: We are getting ripped off, big time, by the pharmaceutical industry.

The good news — and there is good news — is that scientists have made some amazing and important discoveries that have saved millions of lives during the global COVID pandemic, and others that have the capacity to save and extend the quality of life for people in this country and around the world.

The bad news — and there is plenty of it — is that those advances in science and technology mean nothing if people cannot afford them.

In this country, we pay over 3 times as much as other major countries for brand name prescription drugs, and, in some cases we pay 10 or 20 times more than the people of other countries for the same exact product.

The result of the high cost of prescription drug costs is obvious: One out of four Americans cannot afford to purchase the prescriptions their doctors write and some die as a result.

And if you think the high cost of prescription drugs is just an individual patient or family problem that may not impact you, I am here to tell you that you are mistaken.

This is also a taxpayer issue. The high cost of these medicines drives up the cost of Medicaid, Medicare, and other public health programs as well as private insurance. When people can't afford the medicine they need and get sicker than they should, they end up in emergency rooms or hospitals at great expense to our already bloated and wasteful healthcare system.

So no matter who you are, no matter how healthy or wealthy you are, this is an issue that impacts ALL OF US.

Yet while millions of Americans struggle to pay for the lifesaving medicine they need and all of us pay the price, the drug companies and their executives have never had it so well.

In 2022, Johnson & Johnson made nearly $18 billion in profits, paid its CEO over $27 million in compensation, and spent over $17 billion on stock buybacks and dividends.

That same year, Merck made $14.5 billion in profit, handed out over $7 billion in dividends to their wealthy stockholders, and paid its CEO over $52 million in compensation.

And Bristol Myers Squibb made $6.3 billion in profits last year, while recently spending over $12 billion on stock buybacks and dividends and giving its CEO over $41 million in compensation.

So where do we go from here?

First, let us acknowledge that we have made SOME progress on the issue of lowering the cost of prescription drugs.

As a result of the Inflation Reduction Act, seniors with diabetes are paying no more than $35 a month for the insulin they need; beginning next year, seniors will be paying no more than $2,000 out-of-pocket a year for prescription drugs; and for the first time in American history Medicare is negotiating with the pharmaceutical industry to lower some of the most expensive prescription drug prices in America.

I am also proud of the accomplishments the Senate Committee on Health, Education, Labor, and Pensions (HELP), which I chair, has made to bring down the cost of prescription drugs.

Months ago, the HELP Committee launched an investigation into the outrageously high price of inhalers that 25 million Americans with asthma and 16 million Americans with chronic obstructive pulmonary disease (COPD) need to breathe.

After talking to the CEOs of the 4 major inhaler manufacturers, three of them have made a commitment to cap the cost of all of their brand name inhalers — Boehringer Ingelheim, AstraZeneca, and GlaxoSmithKline — to $35 at the counter, a substantial reduction in price. Up to this point Tevla has refused to join its competitors and lower its prices.

Last year, the CEO of Moderna committed during a HELP Committee hearing that his company would set up a patient assistance program so that no one in America would have to pay for their vaccine out of pocket.

In a separate HELP Committee hearing last May, the CEO of Eli Lilly committed that his company would not raise prices on existing insulin products after announcing very substantial price cuts for these products.

These efforts will improve life for millions of Americans. They will prevent unnecessary deaths, ease suffering, and save substantial sums of money for working class families.

But, despite all that we’ve accomplished, it is not enough. Not even close. Much more has to be done.

First, it is not just seniors who should be paying no more than $2,000 a year for prescription drugs — that must be made universal and extend to ALL Americans. Period. No matter what their health condition or how many prescription drugs they use, no one should pay more than $2,000 a year out-of-pocket.

There are also individual drugs like Ozempic, made by Novo Nordisk, that have the potential to be game changers in the diabetes and obesity epidemics. Yet, Americans are being charged outrageous and unsustainable prices for these products. We pay about $1,000 a month for this drug while the same exact product can be purchased for just $155 a month in Canada and just $59 in Germany. That may make sense to somebody, but not to me.

If we do not substantially reduce the price of this drug, millions who need it will be unable to afford it. Further, this extremely high price has the potential to bankrupt Medicare, the American people, and our entire healthcare system.

Further, we can no longer tolerate Astellas and Pfizer charging Americans with prostate cancer over $165,000 for Xtandi when that exact same product can be purchased for just $20,000 in Japan.

But it is not just these drugs — it is often the case that Americans are paying far more than people in other countries for the same exact medicines.

All over this country, the American people are asking why it is that they pay, by far, the highest prices in the world for prescription drugs?

The answer is simple. It is because drug companies in America are allowed to charge whatever they want. And that’s what they do. Their business model is not about how they can save and improve the lives of as many people as possible — it is about maximizing profit. And that is something that should offend everyone.

I have introduced legislation to cut the price of prescription drugs by at least 50% by preventing the pharmaceutical industry from charging more for medicine in the U.S. than they do in Canada, Britain, Germany, France, and Japan — a concept that is not only supported by progressives, but former President Donald Trump.

I have also introduced legislation to allow patients, pharmacists, and wholesalers to purchase affordable prescription drugs from Canada, the United Kingdom, and other major countries with strong safety standards.

I will soon be introducing legislation that would greatly expand Medicare’s ability to negotiate the price of prescription drugs.

Working together, we can take on the greed of the pharmaceutical industry and substantially lower the price of prescription drugs in America.

Yes. There are many issues which divide the American people — but not this one. Whether you are a Democrat, Republican, or Independent, a progressive or conservative, you understand that the extraordinary greed of the pharmaceutical industry must be ended.

When we do that, we will be improving the quality of life for millions of Americans while lowering the cost of healthcare in this country which is at least double that of any other wealthy country.

Let’s do it.

Bernie Sanders

[alixgracchus]

E. NIGMA: PRIVATE INVESTIGATOR

A TV show in eight episodes about Batman's most cunning villain of his rogue gallery: the Riddler! Eddie Nigma has finally decided to go straight and serve the public good with his impressive intellect — for a price. Mysteries and challenges abound in Gotham City, but will they keep Nigma away from his old life of crime?

S01E01: THE WONDERS OF CATHAY

Eddie Nigma is tasked by the Gotham Museum of finding the culprits behind the robbery of the newest exhibition of recently acquired ancient Chinese artefacts. Things get complicated when he finds the thieves dead – and their heart missing. The only clue seems to be the shattered pieces of a Shang dynasty vessel. Soon however, Nigma has a more pressing matter: a string of attacks involving a fox-like creature who devours the hearts of its male victims. Could it be that a broken vase has unleashed something wicked in Gotham City?

S01E02: THIRTEEN ANGRY MEN

D. A. Saratoga quietly hires Nigma when her trial against murderous starlet Mindy “Baby Doll” Logan is disrupted by the death of a juror in a closed room with eleven other people. Is this a machination from the angelic-looking Logan or is this much more personal?

S01E03: THE BLACK CAT

A wealthy businessman hires Eddie to protect a famous artwork by Théophile-Alexandre Steinlein during its exposition in an art gallery. What should have been easy money becomes a headache when Nigma finds himself face-to-face with an old friend with nine lives…

S01E04: AMOR VINCIT OMNIA

Mabel’s childhood friend hires Nigma to investigate the disappearance of her fellow successful showgirl Narjisse Lamar. The detective soon finds himself entangled in a deadly love triangle with rising mob boss Gianny Pisanello…and Jonathan Crane, aka the Scarecrow.

S01E05: L'APPEL DU VIDE

When a newly commercialized antidepressant turns out to have devastating side effects, it is up to Eddie Nigma to make sure Helms Pharma’s parent company doesn’t get to sweep the scandal under the rug until they can sell their stocks. But when said parent company is none other than Wayne Enterprises, can the detective truly match with the prince of Gotham?

S01E06: I AM VENGEANCE

When Nigma receives a single lock of hair and an ominous riddle, strange events and nightmares start befalling him. It soon appears the hair is from teenage oil heiress Ethel Declan, who got killed twenty years ago during a botched heist by the Riddler. Things go from worrying to creepy when Eddie becomes plagued by visions of the dead girl. Is her vengeful spirit back from the dead or is someone else seeking revenge?

S01E07: SARATOGA'S DEVIL

Commissioner Gordon reluctantly asks for Nigma’s help when D.A. Saratoga goes missing, leaving behind only a trail of coded messages. The modus operandi appears to be the one of the Astrologer, who was none other than Saratoga’s first client as a lawyer fresh out of law school. The man has always maintained his innocence…until his death ten years ago. Eddie must dig out the past if he wants to save Saratoga in time and uncovers who truly is the Astrologer.

S01E08: STAR-CROSSED LOVERS

Donna Troy hires Eddie Nigma to investigate what is happening in Joliemont clinic, where her childhood friend Dick Grayson is being treated after a suicide attempt. Troy believes Wayne is covering her friend’s death up to steal the money left by the Hayley Circus. The truth seems much darker when Nigma discovers famed mercenary Deathstroke has seemingly kidnapped the young man. Yet the detective cannot help but feel that not is all what it seems, especially when he finally understands that Dick Grayson is none other than Nightwing… Deathstroke’s longtime nemesis.

Dedicated to @talesfromthenorsesmouth @enigmainvestigations and all the PI!Riddler blogs out there: thank you, you give me so much joy! Also dedicated to my good pal @noah-kuttler from the good old days.

#edward nigma #riddler #edward nygma #dcedit #dcuedit #e. nigma: private investigator #mine dcu

[starseedpatriot]

TRUMP directly, publicly goes after the CIA. PENTAGON and puts them in the [ KILLBOX]

When have you ever seen this happen throughout the world by anyone else in recent history?

And lived to tell about it?

> CIA . PENTAGON [ DS] who controls half of the world through military coups. Colour revolutions they created and killed thousands of oppositions in several countries and their Presidents. Their Elites, their countryman.....>> The CIA KILLING MACHINE OF THE>>> ROCKEFELLERS. ROTHSCHILDS VATICAN JESUITS.33RD MASONS SKULL IN BONES ECT ECT ECT ECT<<<<= is the most deadly FORCE in history! [ They] CONTROL and create the world wars , central world banking systems... They created the virus. VACCINES. The PLANDEMIC. The bioweapons, ECT ECT ECT<<<<

.....But Now TRUMP is PUBLICLY going after them, TRUMP is also publicly calling out the RUSSIAN War that was created by the BIDENS regimen and CIA INDUSTRIAL Military complex system///////.

.... No President in history has gone after the CIA and lived too tell about it.. The last President to do so was JFK </// NOW Trump is poised to bring down the FBI. CIA. [ DS] PENTAGON. BIDEN. >> OBAMA regimen.////

______

The only way to bring the [ DS] deep state military intelligence.cia. Pentagon is through>> White HATS U.S. Military OPERATIONS////

>You always have to REMEMBER Trump was placed by Military World Alliance Operations...... This is why TRUMP is protected and why TRUMP IS GOING AFTER THE MOST DANGEROUS KILLING MACHINE ON THE PLANET>> THE CIA. PENTAGON DARPA REGIMEN THAT IS DIRECTLY CONNECTED TO MOSSAD [ DS] MI6 ... OBAMA'S FIVE EYES AGENCIES///////

_As the worlds most POWERFUL banks in EU >> ROTHSCHILDs who controlled the world central banking system for 200 years and NOW is going bankrupt and went into private banking and being delisted from the French stock markets and EU markets

, The obvious [ COLLAPSE] of the ROTHSCHILDS is taking place........ ///// And the CIA is desperate for money and Biden [ DS] government are trying to send as much money as possible to the UKRAINE MONEY LAUNDERING OPERATIONS that funnels back to funding the world pandemic. Payimg off the World health care systems each country., Doctors, hospitals, health establishments in each country. Including financing the scientific community and through the world...... Including all of BLACKROCK , VANGUARD, STATE STREET world insurance agencies over 800,000 companies companies through the world.....///// As the COLLAPSE is happening,... investors are jumping ship world wide by the MILLIONS<<<<

_ 🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥 Yes the CIA. > Money laundering scheme is in huge trouble. The CIA. NATO.UN. EU .U.S. DEEP STATE REGIMEN IS HUGE >>>>FREE FALL....

>>AND TRUMP IS COMING AFTER THE CIA ......... MILITARY OPERATIONS are coming OVERT/////

[ EPSTEIN]

BIDEN. Hunter.

Congressional hearings.

EXPOSURE OF GAIN OF FUNCTION.

EXPOSURE OF THE VIRUS

EXPOSURE OF THE CIA. FBI.

EXPOSURE OF UKRAINE LABS

EXPOSURE OF PLANDEMIC

EXPOSURE OF TWITTER. ( FACEBOOK. YOUTUBE GOOGLE... COMING<<=/)

EXPOSURE of Money laundering SYSTEM into UKRAINE.

EXPOSURE of DAVOS

EXPOSURE OF WHO.CDC.NIH

EXPOSURE Election FRAUD

EXPOSURE CIA DARPA controlling big TECH big pharma

EXPOSURE

EXPOSURE

ECT ECT ECT ECT ECT ECT....

The whole damn house is coming down 🔥....

The WAR to end all WARS

Inside the Storm.

______

TRUMP is on the WAR PATH

WAR PAINT .... EYES ON [ CIA]]FBI. DARPA [ DS] REGIMEN

_

Keep watching TRUMP as he drops COMMS:

______

THE HUNTERS BECOME THE HUNTED. Q

[commonsensecommentary]

America’s “Great Revulsion” Of 2022

It is the time of the year for election forecasts. 

So far, as is the case with most prognosticators, my record is somewhat mixed.  However, I will, nonetheless, foolishly go where wise men fear to tread and offer up my best guesses for the upcoming 2022 midterm elections.

The single issue likely to drive this election is apparent every time we walk into a grocery store, fill a prescription, or gas up our cars: galloping, relentless, corrosive price inflation.  Now stealing our wages at a rate not seen for 40 years, the escalating cost of simply surviving is driving Americans ever deeper into debt and prompting many to make horrid decisions between paying for food, medicine, or heat with the coming of this winter.  Financial stress and insecurity is striking deep into many households, and no relief seems to be in sight.  The mealymouthed responses of Joe Biden and his band of blithering economic advisors to this economic crisis have inspired little confidence and engendered much anger.

The concerns that Americans have about crime and public safety are also having a huge impact on voters.  Continuing Democratic policies that defund and denigrate the police, release those arrested for supposedly minor crimes without charges, and eliminate a bail system that has historically helped to keep those charged with violent crimes locked up until their trials have forced many frightened Americans to buy guns—and now Democrats want to take away that remaining protection too.  

Convincing Americans that their Party has no interest in catching and convicting criminals is a rather bizarre way for Democrats to try to win the 2022 election cycle.

Of course, the Democrats' most cherished hope is that abortion politics will prove decisive, but the post-Dobbs fervor of only a few months ago seems to have faded.  Worse still for Democrats, both Black and Hispanic voters are clearly not the monolithic bloc of dependably Blue ballots they are often presumed to be, and the functional limits of relentless identity politics, which were recently revealed by the racial and ethnic train wreck now transpiring in the raucous Los Angeles City Council, might become even more apparent when the final vote totals are tallied on November 8th.

The polls now show that a number of Democrats involved in races for the Senate, House, and Governorships are dealing with slipping support, and frantically waving the talisman of Donald Trump and shouting about right wing extremism apparently have lost their magical ability to move moderate voters into the Democratic column.

The escalating cost of living is a huge crisis.  Crime is a big issue.  Attempting to forgive students loans in order to buy some votes at taxpayer expense seems not to have resonated with most voters as the Bidenistas hoped it would, and the fatiguing and futile attempts of Democrats to milk the pandemic panic for every penny are turning off Americans, who are beginning to suspect that their lives were turned upside down in order to both justify massive Blue State bailouts and jack up the stock prices of Big Pharma so that members of Congress could cash in.

Moreover, the continuing scandal of nearly non-existent border security, resulting in millions of illegal immigrants entering our country, is hard to miss despite every effort by Democrats to ignore or downplay this problem.  Furthermore, watching Joe Biden humiliate himself and our nation by begging Saudi Arabia and Venezuela for the oil he refuses to allow American companies to pump domestically is a public proclamation of both his idiocy and weakness.  We also cannot ignore foreign policy missteps that have, according to Joe Biden himself, raised the terrifying specter of a nuclear exchange on the battlefields of Ukraine.  And who can forget the debacle of our precipitous and halfwitted withdrawal from Afghanistan, which was a case study in inept leadership by our brain dead Commander-in-Chief?

Nothing is now going right for America, but I suppose we can be thankful that the so-called Inflation Reduction Act that was signed in August, which was never intended to bring down inflation in the first place, has ensured that the IRS can hire tens of thousands of new agents so that our income taxes can be more easily audited.  Another dose of hundreds of billions of dollars of federal borrowing to fund its many other provisions will help to force interest rates higher for the foreseeable future, keep lots of D.C. lobbyists employed, and ensure that less money will be available for the true emergencies facing America and Americans.  Hooray.

Unsurprisingly, President Biden and his hapless sidekick, a Vice President who seems only slightly less clueless than her flailing boss, are both distinctly unpopular.  Their ranting dislike for at least half of the American population—those who, incidentally, do most of the work, spill most of the blood, and fly most of the flags in our nation—is both abundantly apparent and supremely distasteful.  It certainly drives national Democrats crazy to have to pretend any concern whatsoever for those Americans who don't reside in Brooklyn or Berkeley, and their Party's disdain and condescension for so many decent and law abiding citizens has driven away a lot of swing voters who find the closet Marxists, gender benders, and Gaia worshippers now driving the Democrat's political and social agenda to be just a bit cuckoo—and scary.

We also cannot ignore another obvious and telling sign that Americans have lost faith in the Democrats running our country into a ditch: Nobody wants to enlist in Joe Biden's Woke military.  When our warriors decide they no longer want to fight for America, it's time to do some serious soul searching about the current direction of our nation.

I am going to go out on a limb, although I really don't think I'm wrong here, and predict that Democrats are due for a pretty significant electoral thumping in just a few weeks.  Given that the last few election cycles have amply demonstrated the electoral polls routinely undercount Republican voters, the fact that the predictive models are showing wholesale Democratic weakness in many previously safe contests would seem to indicate that the reality is a Republican Wave that could easily turn into a Red Tsunami.

The frustrations Americans are now feeling remind me, to be perfectly honest, of the disgust directed at the Democrats in 2016.  Just as in that election, I suspect many will not be voting for Republicans because they are enamored with a specific candidate or their platform; they will, instead, be voting against Democrats.  The 2022 elections will, I believe, go down in history as "The Great Revulsion" directed against Democrats, their policies, and the incredible incompetence featured in the Oval Office and beyond.

Donald Trump was lifted into the Oval Office by the anger many voters felt toward Hillary Clinton and the Democrats.  I believe we are seeing a similar dynamic today.  Joe Biden is the poster child for every aimless, ineffective, expensive, intrusive, and extremist policy now being championed by the ultra-liberal left wing of his party.  

Whether we are talking about forcing biological boys into the girls' locker rooms of our nation's schools, turning every issue facing our country into a racial conflict, or insisting that abortion right up to the point of a live natural birth is not flirting with infanticide, Democrats have firmly and fanatically planted themselves on the wrong side of most of the voters in this nation, many of whom are moderates who are fed up with ideological warfare and overt censorship masquerading as sensible governance.

It seems impossible to believe there will not be a terrible price to be paid at the ballot box for betraying our nation and its citizens in so many ways, and we will learn just how thorough this repudiation will be in only a few short weeks.

This will not be a Revolution: we’re simply revolted by where our country is being dragged without our consent by crazies.

#2022 #democracy #democrats #donald trump #election 2022 #extremism #fear #government #joe biden #leadership #liberalism #marxism #political polarization #protest #republicans #social welfare #voter anger #voting

[anuuuj123]

Exploring Healthcare Solutions: Where to Shop Mankind Pharma Products

In the realm of pharmaceuticals and healthcare, Mankind Pharma stands out as a trusted name, offering a diverse array of medications and wellness products designed to improve lives and promote well-being. Whether it's addressing common ailments or providing innovative healthcare solutions, Mankind Pharma is committed to delivering quality products that meet the evolving needs of consumers. If you're seeking to purchase Mankind Pharma's offerings, it's essential to know where to find them. Let's explore where you can shop Mankind Pharma products and access the healthcare solutions you need.

Mankind Pharma's extensive product range encompasses various therapeutic categories, including pharmaceuticals, over-the-counter medications, and personal care products. From pain relief and respiratory care to skincare and nutritional supplements, Mankind Pharma caters to diverse healthcare needs with efficacy and affordability in mind.

When it comes to shopping for Mankind Pharma products, several options are available to consumers, ensuring accessibility and convenience. One of the primary avenues is through brick-and-mortar pharmacies and drugstores. Mankind Pharma's products are widely distributed across pharmacies, making it convenient for individuals to purchase them locally. Whether you visit independent pharmacies or chain retailers, you're likely to find a selection of Mankind Pharma's offerings on their shelves.

In addition to physical stores, the digital landscape offers ample opportunities to shop for Mankind Pharma products online. Many e-commerce platforms and online pharmacies stock Mankind Pharma's products, allowing customers to browse, purchase, and have their orders delivered to their doorstep. Whether you prefer the convenience of shopping from your mobile device or the vast selection available on e-commerce websites, online shopping provides a seamless and efficient way to access Mankind Pharma's healthcare solutions.

Furthermore, Mankind Pharma operates its own official website, where consumers can explore the company's product portfolio, learn about their offerings, and make purchases directly. The official website often provides detailed information about each product, including indications, dosage instructions, and safety precautions, empowering consumers to make informed decisions about their healthcare needs.

It's important to note that when shopping for Mankind Pharma products, consumers should prioritize purchasing from authorized and reputable sources. This ensures the authenticity, quality, and efficacy of the products, safeguarding against counterfeit or substandard medications.

Conclusion,

whether you're in need of prescription medications, over-the-counter remedies, or personal care products, Mankind Pharma offers a comprehensive range of healthcare solutions. By leveraging a combination of physical pharmacies, online retailers, and its official website, Mankind Pharma ensures that consumers can access its products with ease and convenience. So, whether you're addressing a specific health concern or simply seeking to maintain your well-being, explore the various shopping options available and discover the healthcare solutions offered by Mankind Pharma

[varshilpackagingsposts]

Varshil Packaging Company

Varshil Packaging is a leading manufacturer of specialized films and label stock in India. We offer a comprehensive range of products, including label stock, release liners, surface protection film, self-protective film, adhesive film, poly film, milk film, and agricultural mulch film. Our state-of-the-art manufacturing unit and highly skilled professionals are committed to providing our customers with the best possible products and services. like Pharma & Medical, Cosmetic & Personal Care, Electronics & Durables, Transport & Logistics, Advertisement & Signage, Liquor & Beer, Lubricants & Oils, Food & Beverages, Offset & Digital Printing Sheets, Retail & Branding Solutions etc.Release Liner have a big impact in many ways throughout our daily lives. Our silicone release paper keeps fresh and tacky a wide variety of adhesives. While normal paper bonds to adhesives, our release paper is specially designed to be easy to pull away, without the risk of it falling off on its own. Basic properties of silicone, this release paper sticks to the adhesives without fusing. Just a little pressure is enough to pull away the coated paper from its adhesive, and the adhesive remains tacky and fresh for its required application of product. We provide solvent less silicone coating with platinum catalyst coated release paper can be made with one side coated (C1S) and two side coated (C2S) comes in various types of release, thicknesses, sizes, colour and more. This Paper can convert it into sheets, rolls and die-cuts, and can also offer them with printed or non-printed back-sides as per requirement raised.

#label stcok #release liners #milk film #poly film

[adwingtechnologies]

School software is a computer program designed to help educational institutions manage their daily operations. It provides a centralized platform for managing tasks such as student registration, attendance tracking, grade management, and scheduling.

This software is designed to streamline administrative tasks, reduce paperwork, and increase efficiency. It can also provide valuable insights into student performance, helping teachers identify areas where students may need additional support.

Overall, school software is a powerful tool that can help educational institutions improve their operations and provide a better learning experience for students.

EduPlus is an advanced Education management software created with students in mind which makes it a user-friendly software for anyone trying it for the first time. The EduPlus onboarding team makes sure that the school software integrates with your school seamlessly by giving you a live demo to help you understand every aspect of the software for better functioning and more efficient use. And for other queries related to EduPlus, our customer support team is always on standby to help you resolve your questions.

Student Registration

Student enquiry

ID Card

Front Office

Class,Section and Category Setup

Fees Management 

Fees Dues Reminder 

School Bus Registration

Transport Management 

Library Management 

Book Issues Date

Stock management

Material  Management

Account Management

Employee Salary Account

Vendor management

Messaging

SMS Integration

Reports

Student List

Notifications

Calender and To Do List

Setup

Website 

Online Facility

Web/Desktop Application

Admin/Operator Login

DOWNLOAD SOFTWARE

CALL US AT

70071-22137

QUICK LINKS

Home About us Services Software Latest Updates Online Shop

SERVICES

Website Designing Best Software Company  Clinic & Hospital Software School Management Software Billing & Accounting Software Medical & Pharma Software

CONTACT

[email protected] [email protected]

We Accept Payment by : RazorPay /Google Pay /Paytm

[tanu001thakur]

Nifty Surrenders Early Rally, Ends Flat After Late Day Sell-Offour page title

                            IMAGE SOURCE:  https://in.investing.com/

Nifty Surrenders Early Rally, Ends Flat After Late Day Sell-Off

The Indian stock market witnessed a dramatic turnaround on Tuesday, with the Nifty 50 index relinquishing all its intra-day gains and closing marginally higher in a late sell-off. Despite a promising start that saw the index climb to new highs, profit-booking and cautious sentiment ahead of key events triggered a sharp decline in the final trading hours.

Early Optimism Fizzles Out:

The day began on a buoyant note, fueled by positive global cues and continued buying in select sectors. IT, pharma, and media stocks led the charge, pushing the Nifty past the 18,100 mark. However, the upbeat mood was short-lived. As the session progressed, investors turned apprehensive. The looming earnings season and concerns about upcoming macroeconomic data releases cast a shadow of uncertainty, prompting profit-taking across the board.

Profit-Booking Takes Center Stage:

With gains shrinking throughout the afternoon, selling pressure intensified in the final hour. Heavy selling in heavyweight stocks like Reliance Industries, HDFC Bank, and Infosys dragged the index down further. The broader market also came under pressure, with most sectoral indices ending in the red.

Factors at Play:

Several factors contributed to the Nifty's late-day reversal:

Profit-taking: After a strong run-up in recent weeks, investors chose to lock in profits ahead of potential headwinds.

Earnings season jitters: With the quarterly earnings season kicking off soon, concerns about company performance and potential earnings misses weighed on sentiment.

Macroeconomic data worries: Upcoming inflation and GDP data releases sparked anxiety among investors, leading to cautious positioning.

Global cues: Mixed signals from international markets further added to the indecisiveness in the domestic market.

Technical Perspective:

From a technical standpoint, the Nifty formed a bearish engulfing pattern on the daily chart. This indicates that sellers overwhelmed buyers in the later part of the session, potentially signaling bearish continuation in the near term. However, the index remains above key support levels, and a decisive breakdown below 17,900 is needed for confirmation.

Market Outlook:

The Nifty's late-day plunge serves as a reminder of the inherent volatility in the stock market. While the overall trend remains positive, investors need to be cautious and remain cognizant of potential risks in the near term. The upcoming earnings season and macroeconomic data releases will be crucial drivers of market sentiment in the coming weeks.

In conclusion, the Nifty's intra-day gains evaporated following a late-day sell-off as profit-taking and cautious sentiment ahead of key events dominated the market. While the near-term outlook remains uncertain, the long-term prospects for the Indian market remain positive, provided supportive global cues and robust corporate earnings emerge.

CONTENT SOURCE:https://bard.google.com/

DO YOU NOW ABOUT THE

[cargoteam]

The Delicate Dance: Mastering Pharma Logistics & Clinical Trial Precision

In the realm of healthcare, where lives hang in the balance, pharma logistics and clinical trial logistics waltz together in a delicate dance. Every vial, every capsule, every meticulously timed delivery forms part of a vital choreography, ensuring medicines reach patients and trials run with unwavering precision. But this intricate performance demands more than just a stage. It requires expertise, meticulous planning, and a commitment to flawless execution.

Pharma Logistics: More than Transporting Pills

Imagine temperature-controlled containers waltzing alongside intricate paperwork, while real-time tracking data pirouettes on digital screens. Pharma logistics transcends mere delivery. It's a symphony of:

Temperature-Controlled Precision: Ensuring vital medicines dance through temperature-sensitive journeys, from production lines to patients' hands.

Regulatory Harmony: Navigating the intricate steps of customs clearance and compliance, where every document pirouettes in perfect synchrony.

Inventory Management Magic: Mastering the art of keeping just the right amount of stock in motion, avoiding costly stumbles and ensuring timely deliveries.

Real-Time Transparency: Utilizing technology to track every pill's journey, providing a seamless flow of information for all stakeholders.

Clinical Trial Logistics: Where Precision Meets Speed

Clinical trials take the pharma waltz to a whole new level. Here, speed and accuracy become the lead dancers, ensuring vital study materials reach research sites on time and in perfect condition. Picture this: Global Coordination: Orchestrating the delivery of drugs, devices, and samples across geographies and time zones, keeping the research in rhythm.

Temperature & Security Pas de Deux: Balancing temperature-controlled precision with secure handling requirements, ensuring participant safety and data integrity.

Kitting & Labeling Elegance: Assembling customized kits with meticulous accuracy, where every label becomes a graceful step in the research process.

Real-Time Data Flow: Keeping investigators and sponsors informed through real-time tracking and data management, ensuring transparency and timely decision-making.

Finding the Perfect Partner:

In this intricate performance, choosing the right logistics partner is key. Look for companies with:

Industry Expertise: Proven experience in handling sensitive pharma and clinical trial materials.

Global Reach and Network: The ability to orchestrate a global waltz, with established connections and local knowledge.

Technology and Innovation: Cutting-edge tracking systems, temperature-controlled facilities, and secure data management platforms.

Regulatory Compliance: A deep understanding of and adherence to strict pharma and clinical trial regulations.

The Grand Finale:

With every vial and every kit delivered on time and in perfect condition, the pharma and clinical trial logistics dance reaches its triumphant finale. Lives are improved, breakthroughs are made, and the world moves one step closer to healthier tomorrows. So, let the symphony of logistics continue, guided by expertise, precision, and a commitment to making a difference, one delicate step at a time

#pharma logistics #clinical trial logistics #Cell and Gene Supply Chain #Pharmaceutical Supply Chain

[medicinedistributors]

Enhancing Patient Care: The Vital Role of Pharma Dealers for Hospitals

Medicine Manufacturing is a major in producing different medicines to cure diseases. So We need to choose: best pharma company in madurai,medicine manufacturing company in madurai, diabetes medicine manufacturers in madurai, pharma distributors in madurai, pharmaceutical distributors in madurai.

When it comes to patient care, hospitals and clinics play a critical role in promoting health and wellness. However, behind the scenes, there is another vital player that often goes unnoticed — medicine distributors. These unsung heroes ensure that hospitals have a steady supply of medicines, making it possible for doctors and healthcare professionals to deliver the best possible care to their patients. In Madurai, medicine distributors play an especially important role in enhancing patient care. Let us explore their important role in more detail.

One of the primary responsibilities of medicine distributors is to ensure that hospitals have access to a wide range of medicines. Their extensive network of suppliers and pharmaceutical companies helps in sourcing medicines, both locally and internationally. This allows hospitals to offer the latest, cutting-edge medications to their patients. Whether it’s life-saving drugs or specialized medications, medicine distributors in Madurai work tirelessly to ensure that hospitals never run out of essential medications.

Apart from sourcing medicines, medicine distributors also focus on the quality and authenticity of the drugs they deliver. They collaborate with trusted pharmaceutical companies and follow stringent quality control measures to ensure that hospitals receive genuine, safe, and effective medicines. This is essential to enhance patient care as it minimizes the risk of adverse effects or ineffective treatments. Medicine distributors in Madurai understand the criticality of this aspect and prioritize patient safety above all.

Another vital aspect where medicine distributors contribute to patient care is through their timely deliveries. They understand the urgent nature of healthcare and strive to deliver medicines promptly. Hospitals rely on them to replenish their medicine stocks quickly, and medicine distributors live up to the challenge. This ensures that doctors have the necessary medications on hand to provide immediate treatment to their patients. Quick and efficient deliveries are essential in emergencies where every second counts in saving lives. Medicine distributors in Madurai have built a reputation for their reliability in this regard.

Furthermore, medicine distributors also provide valuable assistance in terms of inventory management. They help hospitals streamline their medicine procurement process, ensuring optimal utilization of resources. By monitoring stock levels, suggesting appropriate quantities, and providing valuable insights, medicine distributors improve the overall efficiency of healthcare institutions. This frees up time and resources for hospitals to focus on patient care rather than getting entangled in administrative tasks.

In conclusion, medicine distributors in Madurai play an indispensable role in enhancing patient care. Their extensive networks, commitment to quality, timely deliveries, and assistance in inventory management make them an essential partner for hospitals and clinics. These unsung heroes ensure that hospitals have a steady supply of medicines, enabling doctors and healthcare professionals to deliver the best possible care to their patients. So, the next time you witness exceptional patient care, remember that behind the scenes, medicine distributors are working tirelessly to make it possible.

Finally, In this blog, help to pick the: medicine distributors in madurai, branded generic medicine suppliers in tamilnadu, branded generic medicine dealers in madurai, branded generic medicine distributors near me, and top pharmaceutical suppliers in madurai.

Contact Us: [phone]

Visit Our Website: https://pharmafabrikon.in/

#best pharma company in madurai #medicine manufacturing company in madurai #diabetes medicine manufacturers in madurai #pharma distributors in madurai #pharmaceutical distributors in madurai #medicine distributors in madurai #generic medicine suppliers in tamilnadu #generic medicine dealers in madurai #generic medicine distributors near me #top pharmaceutical suppliers in madurai #Which is No 1 pharma company? #Which pharma company is best to work? #Which are the top 10 pharma companies? #Which pharma company gives highest salary? #madurai pharma company list #pharma company vacancy in madurai #pharma company in chennai #pharma jobs #pharmafabrikon #Which is the No 1 medicine company? #What are the top medicine manufacturing companies? #Who is the No 1 medicine manufacturer in India? #Who is the largest pharma manufacturer? #pharma sales executive jobs in madurai #Who are the top 3 pharmaceutical wholesale distributors? #How do I start a pharmacy distributor? #What is the income of pharma wholesale distributors? #Who are the largest pharma wholesalers? #How can I become medical distributor? #How much medicine distributors earn?

[meghnasharama-blogs]

Crafting a Stellar Career as an International Business Correspondent

Introduction:

In an era of global commerce, the stories that drive industries need narrators who grasp the breadth and depth of international business. Enter the International Business Correspondent, a specialist weaving tales of global trade, mergers, acquisitions, and market dynamics. But what does it take to be that narrator? An Online MBA in International Trade Management might be your passport. Dive in, as we unravel the journey from a virtual classroom to the global stage.

Embarking on the Online MBA Journey in International Trade Management:

Comprehensive Curriculum: An MBA in international trade management provides a deep understanding of global markets, trading laws, and business strategies.

Global Network: Online platforms allow students to build a worldwide network, an invaluable resource for future correspondents.

Real-time Case Studies: Modern MBA courses utilize live case studies, offering insights into current global business scenarios.

Potential Industries for the International Business Correspondent:

Every industry has a story waiting to be told. As a correspondent:

Technology: Chronicle the rise of startups, tech mergers, and digital disruptions.

Healthcare: Report on global health trends, pharma breakthroughs, and medical innovations.

Banking and Finance: Dive into stock market dynamics, mergers, acquisitions, and financial regulations.

Energy: Explore the world of oil moguls, renewable energy innovations, and global energy policies.

Manufacturing: Narrate tales of production breakthroughs, supply chain dynamics, and industry challenges.

Navigating the Challenges:

Keeping Up With Rapid Changes: Global business is ever-evolving. Staying updated is paramount.

Cultural Sensitivity: Covering stories from different regions requires understanding and respecting varied cultural nuances.

Fact-Checking: In a world of fake news, ensuring accuracy and authenticity in reporting sets professionals apart.

Top 10 Companies in India Looking for International Business Correspondents:

The Times of India Group

NDTV

Reliance MediaWorks

Zee Entertainment Enterprises

The Hindu Group

Bennett, Coleman & Co. Ltd.

Network 18 Group

The Indian Express Group

ABP Pvt Ltd.

Hindustan Times Group

Weighing the Impact of an Online MBA for this Role:

Opting for an MBA is a pivotal decision. Here's why it’s invaluable:

Skill Enhancement: Beyond business acumen, hone skills in research, analytics, and storytelling.

Networking Opportunities: Interactions with global peers and faculty offer rich perspectives and contacts.

A Competitive Edge: In a saturated job market, an MBA from a reputed institute can set you apart.

Let ShikshaGurus help you in your Education Journey:

ShikshaGurus assists you in exploring and comparing courses from over 60 online and distance learning universities. They offer free, unbiased consultation sessions with experts to guide you in selecting the ideal educational path. Furthermore, they provide assistance in finding the best university that aligns with your budget.

Conclusion:

Being an International Business Correspondent is not just about reporting; it's about narrating the sagas of global business landscapes. And while raw passion is essential, complementing it with an Online MBA in International Trade Management could be your blueprint for success. So, if you envision yourself elucidating global business tales, this might just be the path for you.

[zenruption]

The Best Financial Investments in Healthcare

Healthcare is one of the most profitable sectors in the world, and there are plenty of investment opportunities to be had too. When investing, you don’t need to start with thousands or even hundreds. You can look for smaller platforms that allow you to put less in, so you can slowly build up your investments over time. 

Photo by Myriam Zilles on Unsplash

The healthcare business investment possibilities cover everything from medical supply manufacturers, technology companies, service providers, pharmaceuticals, and even assisted living business opportunities.

How can you invest in healthcare? 

There are several ways that you can invest in healthcare; some of them you may have heard of, while others might be nice. 

REITs are healthcare real estate and involve things like seniors living, medical offices and hospitals, or other medical facilities. 

ETFs are healthcare exchange-traded funds, which means you can gain access to many companies but a single product. 

Stocks are something that most people are comfortable with and understand, and there are a lot of options and sub-industries within the healthcare field that are open to investments. 

Directly into a business is as possible and will give you a more hands-on role.

Should you always invest in the most expensive stocks?

There is a big difference between the most valuable stock and the most expensive. Expensive stock can be hundreds or thousands per single stock, and that gives you a relatively small position to start with. 

Keep in mind that during the big gold rush, people made money in two ways, one was the shovels used to dig, and the other was the digging itself. In the care of healthcare, you can look at the supply chain and look for a lower-cost stock. 

And not all expensive stocks are good stock. 

What industries can I look at within the healthcare sector? 

Healthcare is a broad term when it comes to just how many opportunities there are for investment. 

Pharma, BioTech & Life Sciences

Life sciences and tools are clinical testing, research services, and analytical tools.

Biotechnology developed vaccinations and other products from live organisms. 

Pharmaceuticals research and development, plus production of products like pills and vaccines from artificial sources

Healthcare Equipment and Services 

Healthcare technology is companies that offer technological tools and services to the sector, platforms, programming and systems, and others.

Healthcare providers and services are things like wholesalers, insurers, healthcare products, those that provide healthcare services, and even distributors. 

Equipment and supplies like bandages, needles, machines, beds, and stethoscopes. 

The healthcare sector is always going to grow; people live longer than ever now, and with new technology, there are serious advancements in treatments and medication. We will likely see more breakthroughs, so investing in. 

It would be best if you always kept in mind that when you make investments, it should never be more than you are prepared to lose, and seeking further financial information and advice from an advisor is a good idea. 

There are a couple of things you can do to help yourself get investment ready, too; here are 3 Things You Need To Do Before Investing — corruption. 

[mediwinpharma]

What is the Pharma Supply Chain and its Challenges?

The pharma supply chain is the lifeblood of the medical industry, the backbone that keeps hospitals stocked with vital drugs and a pharma company reloaded with necessary medications. It encompasses a vast and intricate network, spanning the globe and connecting manufacturers, distributors, retailers, healthcare providers, and patients.

Imagine the very magnitude of the job at hand. With millions of lives hanging in the balance, this complex dance of precision and coordination takes on enormous importance. However, a host of challenges creeps beneath the surface of this awe-inspiring marvel that threatens to disrupt the seamless flow of healthcare.

This article will illuminate the heart of the pharma supply chain, exploring the challenges overrunning its every step.

What is a Pharma Supply Chain?

The pharma supply chain is the network of steps and processes applied in getting medicines from the companies that produce them to the patients who rely on them. You are an important part of this chain, ensuring the medicines are stored, transported, and delivered safely and on time.

It all starts with the top pharma companies in India that create the medicines. They conduct research, develop new drugs, and produce them according to strict quality standards. Once the pharmaceutical company makes the medicine, your job begins.

How Does a Pharma Supply Chain Work?

The pharma supply chain involves many steps. Here is how it works:

Step 1: Making Medicines

The process starts with the production of medicines. Scientists and researchers develop new drugs. They carefully make them as per strict quality standards. They test them to ensure their safety and effectiveness.

Step 2: Getting Raw Materials

Medicines are made with raw materials and active ingredients. These materials are sourced from a trusted pharmaceutical company. This ensures they meet quality standards and regulatory requirements.

Step 3: Making and Packaging

Once the raw material is ready, they are converted into medicines. Skilled workers use specialized equipment to make and package the medications securely. Your attention to detail is important to ensure that everything is correct.

Step 4: Distribution and Transport

Now it's time to deliver the medicines to the needy ones. It involves distribution and transportation. You must manage inventory and organize warehouses. You must coordinate the safe and timely delivery of medicines. These medicines are delivered to pharmacies, hospitals, and other healthcare facilities.

Step 5: Following the Rules

The pharma supply chain follows regulations and laws to ensure safety and compliance. Confirm all the necessary permits, licenses, and paperwork are in order. Following Good Distribution Practices and regulatory guidelines ensures everything is legal and ethical.

Step 6: Checking Quality

Quality is critical in healthcare. You are accountable for monitoring and maintaining high-quality standards throughout the supply chain. Regular checks, inspections, and tests ensure the medicines are safe, effective, and authentic.

Step 7: Working Together

Collaboration is key! You work with healthcare providers, pharmacies, and hospitals. You learn about their needs and ensure a steady supply of medicines. By communicating and sharing information, you can better understand their demand.

This ensures the right medicines are available when and where they are needed.

Top 5 Challenges Faced by Pharma Supply Chain

The pharma supply chain faces various challenges. Here are those challenges:

1. Following Rules and Regulations

The biggest challenge is understanding and complying with the complex rules and regulations. These rules and regulations govern the pharma supply chain.

Different countries have different requirements for making, storing, and transporting medicines. Pay close attention to these rules. Also, keep accurate records to avoid delays or penalties.

2. Managing Temperature-sensitive Medicines

Some medicines need to be kept at specific temperatures to maintain their effectiveness. This requires proper infrastructure and monitoring systems. It also requires careful handling. It ensures that medicines stay under the required temperature range.

This must happen throughout the supply chain. If the temperature is not maintained, the medicines may lose their strength.

3. Predicting Demand and Managing Inventory

It can be tough to accurately predict how much of each medicine will be needed at any given time. Changes in patient demand, market conditions, and unexpected events affect the demand.

Balancing inventory levels to prevent shortages while avoiding excess stock requires careful forecasting. It also requires efficient inventory management practices.

4. Dealing with Fake or Poor-quality Medicines

Counterfeit and substandard medicines are a serious concern in the pharma supply chain. These fake or poor-quality medicines can put patients at risk. They also damage the reputation of a pharma company and the healthcare system.

Preventing and detecting these counterfeit medicines requires implementing measures. These include product serialization, authentication technologies, and improved supply chain visibility.

5. Navigating a Complex Global Supply Chain

The pharma supply chain often involves many countries, suppliers, and transportation networks. This can be challenging to coordinate. Differences in language, customs regulations, and potential disruptions can complicate the process.

Effective communication and collaboration are crucial to running the supply chain.

Conclusion

The pharma supply chain is a complex network. It ensures life-saving medications reach the needed hands. From pharmaceutical manufacturing to distribution, this complex system faces various challenges. These need careful navigation and innovative solutions.

Moreover, if you want to partner with a trusted pharma company, consider Mediwin Pharma, as they have a well-developed supply chain that helps them to export to several countries. With a proven legacy in the market, Mediwin has earned an excellent reputation. Their commitment to quality and range of medications cater to diverse therapeutic needs, ensuring patients receive the best care, making it the best pharmaceutical company in Gujarat.

Source link

#Pharma Company #pharmaceutical company #top pharma companies in India #pharmaceutical company in gujarat

[xtruss]

Illustration By Berke Yazicioglu of Besuited Business People riding a Chariot that is pulled by mesh renderings of two Bulls.

Will A.I. Become The New McKinsey?

The technology, as it’s currently imagined, promises to concentrate wealth and disempower workers. Is an alternative imaginable?

— By Ted Chiang | May 4, 2023 | Annals of Artificial Intelligence

When we talk about artificial intelligence, we rely on metaphor, as we always do when dealing with something new and unfamiliar. Metaphors are, by their nature, imperfect, but we still need to choose them carefully, because bad ones can lead us astray. For example, it’s become very common to compare powerful A.I.s to genies in fairy tales. The metaphor is meant to highlight the difficulty of making powerful entities obey your commands; the computer scientist Stuart Russell has cited the parable of King Midas, who demanded that everything he touched turn into gold, to illustrate the dangers of an A.I. doing what you tell it to do instead of what you want it to do. There are multiple problems with this metaphor, but one of them is that it derives the wrong lessons from the tale to which it refers. The point of the Midas parable is that greed will destroy you, and that the pursuit of wealth will cost you everything that is truly important. If your reading of the parable is that, when you are granted a wish by the gods, you should phrase your wish very, very carefully, then you have missed the point.

So, I would like to propose another metaphor for the risks of artificial intelligence. I suggest that we think about A.I. as a management-consulting firm, along the lines of McKinsey & Company. Firms like McKinsey are hired for a wide variety of reasons, and A.I. systems are used for many reasons, too. But the similarities between McKinsey—a consulting firm that works with ninety per cent of the Fortune 100—and A.I. are also clear. Social-media companies use machine learning to keep users glued to their feeds. In a similar way, Purdue Pharma used McKinsey to figure out how to “turbocharge” sales of OxyContin during the opioid epidemic. Just as A.I. promises to offer managers a cheap replacement for human workers, so McKinsey and similar firms helped normalize the practice of mass layoffs as a way of increasing stock prices and executive compensation, contributing to the destruction of the middle class in America.

A former McKinsey employee has described the company as “capital’s willing executioners”: if you want something done but don’t want to get your hands dirty, McKinsey will do it for you. That escape from accountability is one of the most valuable services that management consultancies provide. Bosses have certain goals, but don’t want to be blamed for doing what’s necessary to achieve those goals; by hiring consultants, management can say that they were just following independent, expert advice. Even in its current rudimentary form, A.I. has become a way for a company to evade responsibility by saying that it’s just doing what “the algorithm” says, even though it was the company that commissioned the algorithm in the first place.

The question we should be asking is: as A.I. becomes more powerful and flexible, is there any way to keep it from being another version of McKinsey? The question is worth considering across different meanings of the term “A.I.” If you think of A.I. as a broad set of technologies being marketed to companies to help them cut their costs, the question becomes: how do we keep those technologies from working as “capital’s willing executioners”? Alternatively, if you imagine A.I. as a semi-autonomous software program that solves problems that humans ask it to solve, the question is then: how do we prevent that software from assisting corporations in ways that make people’s lives worse? Suppose you’ve built a semi-autonomous A.I. that’s entirely obedient to humans—one that repeatedly checks to make sure it hasn’t misinterpreted the instructions it has received. This is the dream of many A.I. researchers. Yet such software could easily still cause as much harm as McKinsey has.

Note that you cannot simply say that you will build A.I. that only offers pro-social solutions to the problems you ask it to solve. That’s the equivalent of saying that you can defuse the threat of McKinsey by starting a consulting firm that only offers such solutions. The reality is that Fortune 100 companies will hire McKinsey instead of your pro-social firm, because McKinsey’s solutions will increase shareholder value more than your firm’s solutions will. It will always be possible to build A.I. that pursues shareholder value above all else, and most companies will prefer to use that A.I. instead of one constrained by your principles.

Is there a way for A.I. to do something other than sharpen the knife blade of capitalism? Just to be clear, when I refer to capitalism, I’m not talking about the exchange of goods or services for prices determined by a market, which is a property of many economic systems. When I refer to capitalism, I’m talking about a specific relationship between capital and labor, in which private individuals who have money are able to profit off the effort of others. So, in the context of this discussion, whenever I criticize capitalism, I’m not criticizing the idea of selling things; I’m criticizing the idea that people who have lots of money get to wield power over people who actually work. And, more specifically, I’m criticizing the ever-growing concentration of wealth among an ever-smaller number of people, which may or may not be an intrinsic property of capitalism but which absolutely characterizes capitalism as it is practiced today.

As it is currently deployed, A.I. often amounts to an effort to analyze a task that human beings perform and figure out a way to replace the human being. Coincidentally, this is exactly the type of problem that management wants solved. As a result, A.I. assists capital at the expense of labor. There isn’t really anything like a labor-consulting firm that furthers the interests of workers. Is it possible for A.I. to take on that role? Can A.I. do anything to assist workers instead of management?

Some might say that it’s not the job of A.I. to oppose capitalism. That may be true, but it’s not the job of A.I. to strengthen capitalism, either. Yet that is what it currently does. If we cannot come up with ways for A.I. to reduce the concentration of wealth, then I’d say it’s hard to argue that A.I. is a neutral technology, let alone a beneficial one.

Many people think that A.I. will create more unemployment, and bring up universal basic income, or U.B.I., as a solution to that problem. In general, I like the idea of universal basic income; however, over time, I’ve become skeptical about the way that people who work in A.I. suggest U.B.I. as a response to A.I.-driven unemployment. It would be different if we already had universal basic income, but we don’t, so expressing support for it seems like a way for the people developing A.I. to pass the buck to the government. In effect, they are intensifying the problems that capitalism creates with the expectation that, when those problems become bad enough, the government will have no choice but to step in. As a strategy for making the world a better place, this seems dubious.

You may remember that, in the run-up to the 2016 election, the actress Susan Sarandon—who was a fervent supporter of Bernie Sanders—said that voting for Donald Trump would be better than voting for Hillary Clinton because it would bring about the revolution more quickly. I don’t know how deeply Sarandon had thought this through, but the Slovenian philosopher Slavoj Žižek said the same thing, and I’m pretty sure he had given a lot of thought to the matter. He argued that Trump’s election would be such a shock to the system that it would bring about change.

What Žižek advocated for is an example of an idea in political philosophy known as accelerationism. There are a lot of different versions of accelerationism, but the common thread uniting left-wing accelerationists is the notion that the only way to make things better is to make things worse. Accelerationism says that it’s futile to try to oppose or reform capitalism; instead, we have to exacerbate capitalism’s worst tendencies until the entire system breaks down. The only way to move beyond capitalism is to stomp on the gas pedal of neoliberalism until the engine explodes.

I suppose this is one way to bring about a better world, but, if it’s the approach that the A.I. industry is adopting, I want to make sure everyone is clear about what they’re working toward. By building A.I. to do jobs previously performed by people, A.I. researchers are increasing the concentration of wealth to such extreme levels that the only way to avoid societal collapse is for the government to step in. Intentionally or not, this is very similar to voting for Trump with the goal of bringing about a better world. And the rise of Trump illustrates the risks of pursuing accelerationism as a strategy: things can get very bad, and stay very bad for a long time, before they get better. In fact, you have no idea of how long it will take for things to get better; all you can be sure of is that there will be significant pain and suffering in the short and medium term.

I’m not very convinced by claims that A.I. poses a danger to humanity because it might develop goals of its own and prevent us from turning it off. However, I do think that A.I. is dangerous inasmuch as it increases the power of capitalism. The doomsday scenario is not a manufacturing A.I. transforming the entire planet into paper clips, as one famous thought experiment has imagined. It’s A.I.-supercharged corporations destroying the environment and the working class in their pursuit of shareholder value. Capitalism is the machine that will do whatever it takes to prevent us from turning it off, and the most successful weapon in its arsenal has been its campaign to prevent us from considering any alternatives.

People who criticize new technologies are sometimes called Luddites, but it’s helpful to clarify what the Luddites actually wanted. The main thing they were protesting was the fact that their wages were falling at the same time that factory owners’ profits were increasing, along with food prices. They were also protesting unsafe working conditions, the use of child labor, and the sale of shoddy goods that discredited the entire textile industry. The Luddites did not indiscriminately destroy machines; if a machine’s owner paid his workers well, they left it alone. The Luddites were not anti-technology; what they wanted was economic justice. They destroyed machinery as a way to get factory owners’ attention. The fact that the word “Luddite” is now used as an insult, a way of calling someone irrational and ignorant, is a result of a smear campaign by the forces of capital.

Whenever anyone accuses anyone else of being a Luddite, it’s worth asking, is the person being accused actually against technology? Or are they in favor of economic justice? And is the person making the accusation actually in favor of improving people’s lives? Or are they just trying to increase the private accumulation of capital?

Today, we find ourselves in a situation in which technology has become conflated with capitalism, which has in turn become conflated with the very notion of progress. If you try to criticize capitalism, you are accused of opposing both technology and progress. But what does progress even mean, if it doesn’t include better lives for people who work? What is the point of greater efficiency, if the money being saved isn’t going anywhere except into shareholders’ bank accounts? We should all strive to be Luddites, because we should all be more concerned with economic justice than with increasing the private accumulation of capital. We need to be able to criticize harmful uses of technology—and those include uses that benefit shareholders over workers—without being described as opponents of technology.

Imagine an idealized future, a hundred years from now, in which no one is forced to work at any job they dislike, and everyone can spend their time on whatever they find most personally fulfilling. Obviously it’s hard to see how we’d get there from here. But now consider two possible scenarios for the next few decades. In one, management and the forces of capital are even more powerful than they are now. In the other, labor is more powerful than it is now. Which one of these seems more likely to get us closer to that idealized future? And, as it’s currently deployed, which one is A.I. pushing us toward?

Of course, there is the argument that new technology improves our standard of living in the long term, which makes up for the unemployment that it creates in the short term. This argument carried weight for much of the post-Industrial Revolution period, but it has lost its force in the past half century. In the United States, per-capita G.D.P. has almost doubled since 1980, while the median household income has lagged far behind. That period covers the information-technology revolution. This means that the economic value created by the personal computer and the Internet has mostly served to increase the wealth of the top one per cent of the top one per cent, instead of raising the standard of living for U.S. citizens as a whole.

Of course, we all have the Internet now, and the Internet is amazing. But real-estate prices, college tuition, and health-care costs have all risen faster than inflation. In 1980, it was common to support a family on a single income; now it’s rare. So, how much progress have we really made in the past forty years? Sure, shopping online is fast and easy, and streaming movies at home is cool, but I think a lot of people would willingly trade those conveniences for the ability to own their own homes, send their kids to college without running up lifelong debt, and go to the hospital without falling into bankruptcy. It’s not technology’s fault that the median income hasn’t kept pace with per-capita G.D.P.; it’s mostly the fault of Ronald Reagan and Milton Friedman. But some responsibility also falls on the management policies of C.E.O.s like Jack Welch, who ran General Electric between 1981 and 2001, as well as on consulting firms like McKinsey. I’m not blaming the personal computer for the rise in wealth inequality—I’m just saying that the claim that better technology will necessarily improve people’s standard of living is no longer credible.

The fact that personal computers didn’t raise the median income is particularly relevant when thinking about the possible benefits of A.I. It’s often suggested that researchers should focus on ways that A.I. can increase individual workers’ productivity rather than replace them; this is referred to as the augmentation path, as opposed to the automation path. That’s a worthy goal, but, by itself, it won’t improve people’s economic fortunes. The productivity software that ran on personal computers was a perfect example of augmentation rather than automation: word-processing programs replaced typewriters rather than typists, and spreadsheet programs replaced paper spreadsheets rather than accountants. But the increased personal productivity brought about by the personal computer wasn’t matched by an increased standard of living.

The only way that technology can boost the standard of living is if there are economic policies in place to distribute the benefits of technology appropriately. We haven’t had those policies for the past forty years, and, unless we get them, there is no reason to think that forthcoming advances in A.I. will raise the median income, even if we’re able to devise ways for it to augment individual workers. A.I. will certainly reduce labor costs and increase profits for corporations, but that is entirely different from improving our standard of living.

It would be convenient if we could assume that a utopian future is right around the corner and develop technology for use in that future. But the fact that a given technology would be helpful in a utopia does not imply that it’s helpful now. In a utopia where there’s a machine that converts toxic waste into food, generating toxic waste wouldn’t be a problem, but, in the here and now, no one could claim that generating toxic waste is harmless. Accelerationists might argue that generating more toxic waste will motivate the invention of a waste-to-food converter, but how convincing is that? We evaluate the environmental impact of technologies in the context of the mitigations that are currently available, not in the context of hypothetical future mitigations. By the same token, we can’t evaluate A.I. by imagining how helpful it will be in a world with U.B.I.; we have to evaluate it in light of the existing imbalance between capital and labor, and, in that context, A.I. is a threat because of the way it assists capital.

A former partner at McKinsey defended the company’s actions by saying, “We don’t do policy. We do execution.” But this is a pretty thin excuse; harmful policy decisions are more likely to be made when consulting firms—or new technologies—offer ways to implement them. The version of A.I. that’s currently being developed makes it easier for companies to lay people off. So is there any way to develop a kind of A.I. that makes it harder?

In his book “How to Be an Anticapitalist in the 21st Century,” the sociologist Erik Olin Wright offers a taxonomy of strategies for responding to the harms of capitalism. Two of the strategies he mentions are smashing capitalism and dismantling capitalism, which probably fall outside the scope of this discussion. The ones that are more relevant here are taming capitalism and resisting capitalism. Roughly speaking, taming capitalism means government regulation, and resisting capitalism means grassroots activism and labor unions. Are there ways for A.I. to strengthen those things? Is there a way for A.I. to empower labor unions or worker-owned coöperatives?

In 1976, the workers at the Lucas Aerospace Corporation in Birmingham, England, were facing layoffs because of cuts in defense spending. In response, the shop stewards produced a document known as the Lucas Plan, which described a hundred and fifty “socially useful products,” ranging from dialysis machines to wind turbines and hybrid engines for cars, that the workforce could build with its existing skills and equipment rather than being laid off. The management at Lucas Aerospace rejected the proposal, but it remains a notable modern example of workers trying to steer capitalism in a more human direction. Surely something similar must be possible with modern computing technology.

Does capitalism have to be as harmful as it currently is? Maybe not. The three decades following the Second World War are sometimes known as the golden age of capitalism. This period was partially the result of better government policies, but the government didn’t create the golden age on its own: corporate culture was different during this era. In General Electric’s annual report from 1953, the company bragged about how much it paid in taxes and how much it was spending on payroll. It explicitly said that “maximizing employment security is a prime company goal.” The founder of Johnson & Johnson said that the company’s responsibility to its employees was higher than its responsibility to its shareholders. Corporations then had a radically different conception of their role in society compared with corporations today.

Is there a way to get back to those values? It seems unlikely, but remember that the golden age of capitalism came after the enormous wealth inequality of the Gilded Age. Right now we’re living in a second Gilded Age, in which wealth inequality is about the same as it was back in 1913, so it’s not impossible that we could go from where we are now to a second golden age. Of course, in between the first Gilded Age and the golden age we had the Great Depression and two World Wars. An accelerationist might say that those events were necessary to bring about the golden age, but I think most of us would prefer to skip over those steps. The task before us is to imagine ways for technology to move us toward a golden age without bringing about another Great Depression first.

We all live in a capitalist system, so we are all participants in capitalism whether we like it or not. And it’s reasonable to wonder if there’s anything you as an individual can do. If you work as a food scientist at Frito-Lay and your job is to invent new flavors of potato chip, I’m not going to say that you have an ethical obligation to quit because you’re assisting the engine of consumerism. You’re using your training as a food scientist to provide customers with a pleasant experience; that’s a perfectly reasonable way to make a living.

But many of the people who work in A.I. regard it as more important than inventing new flavors of potato chip. They say it’s a world-changing technology. If that’s the case, then they have a duty to find ways for A.I. to make the world better without first making it worse. Can A.I. ameliorate the inequities of our world other than by pushing us to the brink of societal collapse? If A.I. is as powerful a tool as its proponents claim, they should be able to find other uses for it besides intensifying the ruthlessness of capital.

If there is any lesson that we should take from stories about genies granting wishes, it’s that the desire to get something without effort is the real problem. Think about the story of “The Sorcerer’s Apprentice,” in which the apprentice casts a spell to make broomsticks carry water but is unable to make them stop. The lesson of that story is not that magic is impossible to control: at the end of the story, the sorcerer comes back and immediately fixes the mess the apprentice made. The lesson is that you can’t get out of doing the hard work. The apprentice wanted to avoid his chores, and looking for a shortcut was what got him into trouble.

The tendency to think of A.I. as a magical problem solver is indicative of a desire to avoid the hard work that building a better world requires. That hard work will involve things like addressing wealth inequality and taming capitalism. For technologists, the hardest work of all—the task that they most want to avoid—will be questioning the assumption that more technology is always better, and the belief that they can continue with business as usual and everything will simply work itself out. No one enjoys thinking about their complicity in the injustices of the world, but it is imperative that the people who are building world-shaking technologies engage in this kind of critical self-examination. It’s their willingness to look unflinchingly at their own role in the system that will determine whether A.I. leads to a better world or a worse one. ♦

— The New Yorker

[martynnikkpharma]

How to start a PCD Pharma Franchise Business in India

Start-up, a business in the pharmaceutical Industry in India requires many documents, registrations, and permissions. But starting a PCD Pharma Franchise Business is very easy. PCD Pharma Franchise business requires very minimum documents and formalities to start the business immediately.

The basic requirements to start a PCD Pharma Franchise is:

Wholesale drug license issued by State Drug Regulators

GST Registration

Investment

But here choosing the best Pharmaceutical Company for your products plays an important role. It is the quality of the product which establishes the company’s name in the Market.

Quality, Efficacy, and Safety are the main three pillars of any Pharmaceutical Company.

Way to Find PCD Pharma Franchise in India for Business Opportunity

Online:

In this new Era of Digital India, Things are much easier than before. You can find anything around this world by just googling it.

In the same way, you can search on Google for the best PCD Pharma Company in India and decide by reading reviews and ratings from others.

Nowadays, Social Media also plays a very important role in our lives. It has the power to make someone. Through social media one can visit the desired profiles of Pharma companies who are offering PCD Pharma franchises and get full information about them along with real people’s reviews.

Offline:

This is a traditional way of finding. One can find a good PCD Pharma Franchise company by asking their contacts and fellows.

Points to look in a PCD Pharma Company:

Company Name: The company name should be known, Catchy, Professional, Pronounceable, and remind able.  It is the most important aspect as you will be known by the company’s name.

Brand Name: The brand name should be unique, remind able, and Pronounceable.

Product Range: Look for a company that has a wide range of products along with affordable prices.

Product Packaging: It should be stable, safe, and catchy. Because the first impression is made on the packaging of any product. 

Stock Availability: If the stock distribution is not top-notch it will ruin all your hard work. It has a bad impact on the chemist or doctor if you can't deliver the products on time. So always try to choose that company which can deliver the products on time to delay any future conflicts.

Promotional Material: Always look for a company that provides promotional materials like visual aids, Literature, Brochures, catch covers, prescription pads, pens, etc. 

Monopoly Rights: The Company should give you monopoly rights in that respective area, which will help you to work freely and will also save you from overlapping other’s business.

Payment Terms: Terms & conditions should be clear and transparent. Always try to be transparent in Business regarding payment and business terms & conditions. 

Certifications: The Company should be WHO-GMP certified and should have all the required certifications by the state regulatory.

Company Background: Always recheck the company’s background. The company should be reputed. It will save you from any future conflicts.

Why MARTYN NIKK PHARMA PRIVATE LTD?

MARTYN NIKK PHARMA is a leading PCD pharmaceutical company for pharmaceutical products and Franchise Marketing. It is one of the best PCD Pharma Franchise Companies in India offering monopoly rights with its top top-quality products and services at affordable prices.

Our aim is to always serve our customers with top-quality products and services.

Quality, Efficacy & Safety:

We never compromise on the quality standards of our Products. Quality is our key focus. Our Products are efficient and safe.

 On-Time Delivery:

Our delivery system is always very simple and smooth which makes the delivery faster and simpler. That means we deliver the products on time or before the given time.

Affordable:

Our products are affordable, which means one can easily start up a business in PCD Pharma Franchise with very less Investments. With affordable prices, we serve top-notch quality services. We never compromise on the quality standards of our products.

Care with Commitment:

We always fulfill our commitments, and there are no hidden terms and conditions. For us, everyone who is getting indulged with us for business is our Family. Join MARTYN NIKK Family.

#pcd pharma franchise business #best pcd pharma franchise business #top pcd pharma franchise business #pharma franchise business #martynnikkpharma #martynnikk #how to start a pcd pharma franchise business